Evaluation of Mammography Performance in the United States: The Breast Cancer Surveillance Consortium

2007 ◽  
Vol 10 (2) ◽  
pp. 89-101 ◽  
Author(s):  
K. Robin Yabroff ◽  
Rachel Ballard-Barbash ◽  
Patricia Carney ◽  
William Barlow
Keyword(s):  
Breast Cancer ◽  
United States ◽  
The United States ◽  
Cancer Surveillance ◽  
Breast Cancer Surveillance Consortium

scholarly journals Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: A report from the Breast Cancer Surveillance Consortium

Cancer ◽  
2015 ◽  
Vol 121 (9) ◽  
pp. 1369-1378 ◽  
Author(s):  
Kimberly H. Allison ◽  
Linn A. Abraham ◽  
Donald L. Weaver ◽  
Anna N. A. Tosteson ◽  
Heidi D. Nelson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Breast Biopsy ◽  
The United States ◽  
Cancer Surveillance ◽  
Breast Cancer Surveillance Consortium

scholarly journals Women's considerations and experiences for breast cancer screening and surveillance during the COVID-19 pandemic in the United States: A focus group study

2021 ◽  
Vol 151 ◽  
pp. 106542
Author(s):  
Karen E. Schifferdecker ◽  
Danielle Vaclavik ◽  
Karen J. Wernli ◽  
Diana S.M. Buist ◽  
Karla Kerlikowske ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Screening ◽  
Focus Group ◽  
Breast Cancer Screening ◽  
The United States ◽  
Focus Group Study ◽  
Screening And Surveillance

scholarly journals Anxiety- and Health-Related Quality of Life Among Patients With Breast Cancer: A Cross-Cultural Comparison of China and the United States

2018 ◽  
pp. 1-9
Author(s):  
Jin You ◽  
Qian Lu ◽  
Michael J. Zvolensky ◽  
Zhiqiang Meng ◽  
Kay Garcia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
United States ◽  
Trait Anxiety ◽  
State Anxiety ◽  
Cultural Context ◽  
The United States ◽  
Cross Cultural ◽  
Chinese Patients

Purpose Literature has documented the prevalence of anxiety and its adverse effect on quality of life among patients with breast cancer from Western countries, yet cross-cultural examinations with non-Western patients are rare. This cross-cultural study investigated differences in anxiety and its association with quality of life between US and Chinese patients with breast cancer. Methods Patients with breast cancer from the United States and China completed measures for anxiety (Spielberger State-Trait Anxiety Inventory) and quality of life (Functional Assessment of Cancer Therapy-Breast). Results After controlling for demographic and medical characteristics, Chinese patients reported higher levels of trait and state anxiety than US patients. Although there was an association between anxiety and quality of life in both groups of patients, the association between state anxiety and quality of life was stronger among Chinese patients than among US patients, with the association between trait anxiety and quality of life the same between the two cultural samples. Conclusion These findings suggest that anxiety and its association with quality of life among patients with breast cancer varies depending on cultural context, which reveals greater anxiety and poorer quality of life among Chinese patients compared with US patients. This suggests greater unmet psychosocial needs among Chinese patients and highlights the need to build comprehensive cancer care systems for a better quality of life in Chinese populations.

scholarly journals Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States

Cancer ◽  
2015 ◽  
Vol 121 (15) ◽  
pp. 2544-2552 ◽  
Author(s):  
Sarah S. Mougalian ◽  
Pamela R. Soulos ◽  
Brigid K. Killelea ◽  
Donald R. Lannin ◽  
Maysa M. Abu-Khalaf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Neoadjuvant Chemotherapy ◽  
The United States ◽  
Stage I

scholarly journals Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Daniel C. Beachler ◽  
Cynthia de Luise ◽  
Aziza Jamal-Allial ◽  
Ruihua Yin ◽  
Devon H. Taylor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Pulmonary Embolism ◽  
Cohort Study ◽  
Real World ◽  
The United States ◽  
Elevated Risk ◽  
Breast Cancer Patients ◽  
Increased Risk ◽  
Serious Infections

Abstract Background There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. Methods We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to September 2017 using the HealthCore Integrated Research Database (HIRD), a longitudinal claims database of commercial health plan members in the United States. The historical comparator cohort comprised patients initiating fulvestrant monotherapy from January 2011 to January 2015. Propensity score matching and Cox regression were used to estimate hazard ratios for various safety events. For acute liver injury (ALI), additional analyses and medical record validation were conducted. Results There were 2445 patients who initiated palbociclib including 566 new users of palbociclib-fulvestrant, and 2316 historical new users of fulvestrant monotherapy. Compared to these historical new users of fulvestrant monotherapy, new users of palbociclib-fulvestrant had a greater than 2-fold elevated risk for neutropenia, leukopenia, thrombocytopenia, stomatitis and mucositis, and ALI. Incidence of anemia and QT prolongation were more weakly associated, and incidences of serious infections and pulmonary embolism were similar between groups after propensity score matching. After adjustment for additional ALI risk factors, the elevated risk of ALI in new users of palbociclib-fulvestrant persisted (e.g. primary ALI algorithm hazard ratio (HR) = 3.0, 95% confidence interval (CI) = 1.1–8.4). Conclusions This real-world study found increased risks of several adverse events identified in clinical trials, including neutropenia, leukopenia, and thrombocytopenia, but no increased risk of serious infections or pulmonary embolism when comparing new users of palbociclib-fulvestrant to fulvestrant monotherapy. We observed an increased risk of ALI, extending clinical trial findings of significant imbalances in grade 3/4 elevations of alanine aminotransferase (ALT).

Sign in / Sign up

Export Citation Format

Share Document